When the coronavirus pandemic struck, CureVac was supposed to be the first to bring a revolutionary vaccine technology to market. Now executives, investors and industry watchers are struggling to understand what went wrong — and whether the company must change its approach to the messenger ribonucleic acid technology it was so critical to advancing. CureVac’s troubles started not long after coronavirus began to spread.
Questor tipped four coronavirus vaccine makers between last August and this April and the black sheep of that family has been CureVac, the German-based but American-listed biotech firm. While shares in BioNTech, Moderna (which we later sold at a large profit) and AstraZeneca have all performed well, especially the former two, those in CureVac have lost more than half their value after it announced disappointing vaccine efficacy last month. Time to throw them into the sharps bin? Much of our inte
CureVac (NASDAQ: CVAC) surprised investors a few weeks ago when it announced disappointing data from a trial of its mRNA vaccine candidate. Many expected the German biotech would follow in the footsteps of fellow mRNA vaccine makers Pfizer and Moderna. After the CureVac report, it looked like company's dreams of a spot in the vaccine market were over -- at least in the near term.